Boehringer Ingelheim Venture Fund

Corporate venture fund investing in early-stage biomedical companies. Initial tickets are commonly in the low single-digit millions of euro with reserves for follow-on rounds.

Boehringer Ingelheim Venture Fund GmbH

private · national

Deadline: rolling — Opportunities reviewed on a rolling basis; no fixed call.

This funder does not publish a success rate. We rank it using the rate observed across similar programmes and label it as an estimate rather than implying we know.

Quick — mostly identity and bank details.